Menu

CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy

Get up to speed on the latest thinking in immune system-powered therapies. Bring your questions and comments for our esteemed speakers.

Feb 13, 2018
The Scientist Creative Services Team

Car T-Cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunology from thescientistllc on Vimeo.


Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability. CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the re-directing of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, The Scientist is bringing together a panel of experts to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types. Join us to get your questions answered by our esteemed panel.

Topics to be covered:

  • Where cancer immunotherapies are living up to their promise, and where they’re falling short
  • The art and science of developing novel immunotherapies

Meet the Speakers:

Bruce Levine, PhD
Netter Professor in Cancer Gene Therapy
Founding Director, Clinical Cell and Vaccine Production Facility
Center for Cellular Immunotherapies Deputy Director
   – Technology Innovation and Assessment
Department of Pathology and Laboratory Medicine
Perelman School of Medicine, Abramson Cancer Center
                           University of Pennsylvania

 

John H. Sampson, MD, PhD, MBA, MHSc
Robert H. and Gloria Wilkins Professor of Neurosurgery
Chair, Department of Neurosurgery
Duke University Medical Center

 


January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!